Takeda Pharmaceutical’s QDENGA approved for use in European Union

Takeda announced that the European Commission granted marketing authorization for the company’s dengue vaccine QDENGA for the prevention of dengue disease in individuals from four years of age in the European Union. QDENGA should be used in accordance with official recommendations. The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use in October 2022.